Get the Stockscreener App
5.305
25.12%
1.065
After Hours:
5.31
0.005
+0.09%
Burning Rock Biotech Ltd Adr stock is traded at $5.305, with a volume of 22,812.
It is up +25.12% in the last 24 hours and up +88.12% over the past month.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
See More
Previous Close:
$4.24
Open:
$4.08
24h Volume:
22,812
Relative Volume:
0.72
Market Cap:
$52.32M
Revenue:
$79.32M
Net Income/Loss:
$-100.37M
P/E Ratio:
-4.9617
EPS:
-1.0692
Net Cash Flow:
$-44.34M
1W Performance:
+14.33%
1M Performance:
+88.12%
6M Performance:
-29.74%
1Y Performance:
-39.37%
1-Day Range:
$4.08
$5.45
1-Week Range:
$4.08
$5.7661
52-Week Range:
$2.62
$9.987
Burning Rock Biotech Ltd Adr Stock (BNR) Company Profile
Name
Burning Rock Biotech Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare BNR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNR
Burning Rock Biotech Ltd Adr
|
5.305 | 52.32M | 79.32M | -100.37M | -44.34M | -1.0692 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Burning Rock Biotech Ltd Adr Stock (BNR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
Burning Rock Biotech Ltd Adr Stock (BNR) Latest News
Canada Multi Cancer Early Detection Market Size & Outlook, 2030 - Grand View Research
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China - GlobeNewswire Inc.
Burning Rock Biotech CFO Leo Li resigns - Investing.com
Burning Rock Biotech Limited Announces the Resignation of Leo Li as Chief Financial Officer - Marketscreener.com
Brazil Multi Cancer Early Detection Market Size & Outlook, 2030 - Grand View Research
Burning Rock Biotech Limited Sponsored ADR (BNR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo New Zealand News
LiveRamp (RAMP) Tops Q2 Earnings and Revenue Estimates - Yahoo New Zealand News
Burning Rock Biotech Limited Sponsored ADR (BNR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo New Zealand News
Outbrain Inc. (OB) Reports Q4 Loss, Tops Revenue Estimates - Yahoo New Zealand News
Rackspace (RXT) Q2 Earnings Surpass Estimates - Yahoo Singapore News
Burning Rock (BNR) in Focus: Stock Moves 5.4% Higher - Yahoo Movies UK
Earnings call: Burning Rock returns to profitability in Q1 2024 By Investing.com - Investing.com
Why Shares of Alibaba, JD.com, and Burning Rock Biotech Are Rising Today - The Globe and Mail
FDA Grants Breakthrough Device Designation to A Multi-Cancer Detecting Blood Test - Cancer Network
What should you do if you own US-listed Chinese stocks ordered by SEC to delist? - Dr Wealth
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
Making it harder to "buy" China, Inc. - US-China Institute
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
BioLine Rx (NASDAQ:BLRX) Stock Quotes, Forecast and News Summary - Benzinga
Burning Rock Biotech (BNR) Stock Price, News & Analysis - MarketBeat
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/ - Benzinga
Citi Appointed Depositary Bank for Burning Rock Biotech Limited’s Sponsored ADR Program - Business Wire
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adv - Benzinga
Burning Rock Biotech Ltd Adr Stock (BNR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):